Cite
HARVARD Citation
Auliac, J. et al. (2021). Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02–15 study). Lung cancer. pp. 122-127. [Online].